GLPBio

Budesonide

Catalog No.: GC11897Purity:>99.50%
COASDSData Sheet
흡입용 글루코코르티컬 스테로이드인 부데소니드(Budesonide)는 경구 활성 글루코코르티코이드 수용체 작용제입니다.

제품은 연구용으로만 사용됩니다. 인체에 사용할 수 없으며 환자에게 판매하지 않습니다.

Budesonide
Cas No.: 51333-22-3
10mM (in 1mL DMSO)In Stock
$41.00
1
100mgIn Stock
$37.00
1
200mgIn Stock
$69.00
1
500mgIn Stock
$156.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

인용 문헌 (Citations)

현재 이 제품에 대한 인용 문헌이 없습니다. 아래는 GlpBio 제품을 인용한 주요 논문입니다.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

제품 설명 (Description)

Budesonide is a glucocorticoid with potent local anti-inflammatory effects. Budesonide enhances the stability of endothelial cells, smooth muscle cells, and lysosomal membranes, inhibits immune responses, and reduces antibody synthesis, thereby decreasing the release and activity of allergic mediators such as histamine. Budesonide is used in the treatment of bronchial asthma, asthmatic chronic bronchitis, allergic rhinitis, nasal polyps, Crohn's disease, and ulcerative colitis[1-4].

In vitro, Budesonide (1μM–25μM) was used to treat LS180 and Caco-2 intestinal cell lines for 48h–72h. Budesonide induced the expression of MDR1/P-gp in LS180 cells and down-regulated the expression of MDR1/P-gp in Caco-2 cells[5]. Budesonide (0.1–25μM) was co-treated with SARS-CoV-2 (MOI=0.1) in Vero E6 cells for 24 hours. Budesonide significantly reduced the viral titer in Vero E6 cells without affecting cell viability[6].

In vivo, Budesonide (10mg/kg/day) was administered daily via oral gavage to female C57BL/6 mice for 5 days. Budesonide significantly increased the mortality rate in Clostridium difficile-infected mice[7]. Budesonide (1mg) combined with Calcitriol (100ng) was administered daily via nebulized inhalation and intraperitoneal injection to asthmatic model BALB/c mice for 8 weeks. Budesonide and Calcitriol synergistically inhibited airway remodeling in asthmatic mice[8].

References:
[1] Olivas I, Cobreros M, Londoño MC, et al. Budesonide in the first line treatment of patients with autoimmune hepatitis. Gastroenterol Hepatol. 2022 Aug-Sep;45(7):561-570.
[2] Grossmann C, Scholz T, Rochel M, et al. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004 Sep;151(3):397-406.
[3] Dong L, Zhu YH, Liu DX, et al. Intranasal Application of Budesonide Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Suppressing Nucleotide-Binding Oligomerization Domain-Like Receptor Family, Pyrin Domain-Containing 3 Inflammasome Activation in Mice. J Immunol Res. 2019 Feb 27;2019:7264383.
[4] Pereira MA, Tao L, Liu Y, et al. Modulation by budesonide of DNA methylation and mRNA expression in mouse lung tumors. Int J Cancer. 2007 Mar 1;120(5):1150-3.
[5] Maier A, Zimmermann C, Beglinger C, et al. Effects of budesonide on P-glycoprotein expression in intestinal cell lines. Br J Pharmacol. 2007 Feb;150(3):361-8.
[6] Heinen N, Meister TL, Klöhn M, et al. Antiviral Effect of Budesonide against SARS-CoV-2. Viruses. 2021 Jul 20;13(7):1411.
[7] Lin Q, Li Z, Lu L, et al. Budesonide, an anti-inflammatory drug, exacerbate clostridioides difficile colitis in mice. Biomed Pharmacother. 2023 Nov;167:115489.
[8] Qian J, Xu Y, Yu Z. Budesonide and Calcitriol Synergistically Inhibit Airway Remodeling in Asthmatic Mice. Can Respir J. 2018 May 2;2018:5259240.

실험 프로토콜 (Protocol)

Cell experiment [1]:

Cell lines

LS180 and Caco-2 cells (human intestinal cell lines)

Preparation Method

LS180 and Caco-2 cells were cultured in Dulbecco's modified Eagle's medium with Glutamax-I, supplemented with 10% fetal bovine serum, 1% non-essential amino acids, 1% sodium pyruvate, 50μg/ml gentamycin. Cells were seeded into 12-well plastic culture dishes and maintained in a humidified 37°C incubator with 5% CO2. Cells were treated with Budesonide (1μM–25μM).

Reaction Conditions

1μM–25μM; 48h

Applications

Budesonide induced MDR1/P-glycoprotein expression in LS180 cells and down-regulated MDR1/P-glycoprotein expression in Caco-2 cells. These changes were confirmed at mRNA, protein, and functional levels.

Animal experiment [2]:

Animal models

Female BALB/c mice (6-8 weeks old)

Preparation Method

Mice were sensitized by intraperitoneal injection of 50μg ovalbumin (Ova) with 1mg aluminum hydroxide on days 1 and 14. From day 21, mice were challenged by inhalation of 1% Ova solution for 30min once daily for eight weeks to establish an asthma model. In the Budesonide treatment group, 0.5h before each Ova challenge, mice inhaled 5mL PBS containing 1mg Budesonide via a nebulizer over 30min.

Dosage form

1mg; inhalation; daily administration before each Ova challenge; 8 weeks

Applications

Budesonide monotherapy alleviated pathological changes including airway eosinophil infiltration, mucus secretion, and collagen proliferation in asthmatic mice. Budesonide inhibited the high expression of collagen type I (COL I), collagen type III (COL III), and α-smooth muscle actin (α-SMA), downregulated the expression of TGFβ type I receptor (TGFβRI), phosphorylated Smad2 (pSmad2), and phosphorylated Smad3 (pSmad3), and upregulated the expression of Smad7 in lung tissue. Budesonide decreased the expression of microRNA-21 (miR-21) in lung tissue.

References:
[1] Maier A, Zimmermann C, Beglinger C, et al. Effects of budesonide on P-glycoprotein expression in intestinal cell lines. Br J Pharmacol. 2007 Feb;150(3):361-8.
[2] Qian J, Xu Y, Yu Z. Budesonide and Calcitriol Synergistically Inhibit Airway Remodeling in Asthmatic Mice. Can Respir J. 2018 May 2;2018:5259240.

제품 문서 (Product Documents)

Purity:>99.50%Appearance:A solid
COASDSData Sheet

화학적 특성 (Chemical Properties)

CAS 번호
51333-22-3
화학명
(6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one
SMILES
O=C(C([H])([H])O[H])[C@@]12OC(C([H])([H])C([H])([H])C([H])([H])[H])([H])O[C@]1([H])C([H])([H])[C@]([C@@](C([H])([H])C3([H])[H])([H])[C@@]4([H])[C@@](C([H])([H])[H])(C([H])=C5[H])C3=C([H])C5=O)([H])[C@]2(C([H])([H])[H])C([H])([H])[C@]4([H])O[H]
분자식
C25H34O6
분자량
430.53
용해도
≥ 20.2mg/mL in DMSO
보관
Store at -20°C
일반 주의사항
제품의 용해도 데이터에 따라 적절한 용매를 선택하십시오. 조제 후에는 반복적인 동결·해동을 피할 수 있도록 저장 용액을 소분하십시오.
저장 용액은 -80°C 보관 시 6개월 이내, -20°C 보관 시 1개월 이내에 사용하십시오.
용해도를 높이려면 튜브를 37°C로 데운 뒤 적절한 시간 동안 초음파 처리하십시오.
배송 조건
평가용 샘플은 아이스팩과 함께 배송됩니다. 그 외 용량은 실온 배송되며, 요청 시 아이스팩과 함께 배송할 수 있습니다.

계산 도구 (Calculators)몰 농도 / 희석 / 분자량 / 단위 변환 / 생체 내 제형 / 용해도

g/mol

Reviews

Review for Budesonide

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%